Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes by Lorente-Cebrian, S. (Silvia) et al.
Clinical Science (2009) 117, 243–249 (Printed in Great Britain) doi:10.1042/CS20090020 243
Eicosapentaenoic acid stimulates AMP-activated
protein kinase and increases visfatin secretion
in cultured murine adipocytes
Silvia LORENTE-CEBRIA´N∗, Matilde BUSTOS†, Amelia MARTI∗,
J. Alfredo MARTINEZ∗ and Maria J. MORENO-ALIAGA∗
∗Department of Nutrition, Food Science, Physiology and Toxicology, University of Navarra, 31008 Pamplona, Spain, and
†Division of Hepatology and Gene Therapy, Center for Applied Medical Research (CIMA), University of Navarra,
31008 Pamplona, Spain
A B S T R A C T
Visfatin is an adipokine highly expressed in visceral AT (adipose tissue) of humans and rodents,
the production of which seems to be dysregulated in excessive fat accumulation and conditions
of insulin resistance. EPA (eicosapentaenoic acid), an n−3 PUFA (polyunsaturated fatty acid), has
been demonstrated to exert beneficial effects in obesity and insulin resistance conditions, which
have been further linked to its reported ability to modulate adipokine production by adipocytes.
TNF-α (tumour necrosis factor-α) is a pro-inflammatory cytokine whose production is increased
in obesity and is involved in the development of insulin resistance. Control of adipokine production
by some insulin-sensitizing compounds has been associated with the stimulation of AMPK (AMP-
activated protein kinase). The aim of the present study was to examine in vitro the effects of EPA
on visfatin production and the potential involvement of AMPK both in the absence or presence
of TNF-α. Treatment with the pro-inflammatory cytokine TNF-α (1 ng/ml) did not modify visfatin
gene expression and protein secretion in primary cultured rat adipocytes. However, treatment of
these primary adipocytes with EPA (200 μmol/l) for 24 h significantly increased visfatin secretion
(P < 0.001) and mRNA gene expression (P < 0.05). Moreover, the stimulatory effect of EPA on
visfatin secretion was prevented by treatment with the AMPK inhibitor Compound C, but not with
the PI3K (phosphoinositide 3-kinase) inhibitor LY294002. Similar results were observed in 3T3-L1
adipocytes. Moreover, EPA strongly stimulated AMPK phosphorylation alone or in combination
with TNF-α in 3T3-L1 adipocytes and pre-adipocytes. The results of the present study suggest
that the stimulatory action of EPA on visfatin production involves AMPK activation in adipocytes.
INTRODUCTION
Visfatin/Nampt/PBEF (pre-B-cell colony-enhancing
factor) is a newly discovered adipokine, which is
mainly produced by visceral AT (adipose tissue) in
both humans and rodents [1]. Conflicting results have
been found regarding the role played by visfatin in
obesity and insulin resistance. In fact, some studies
have shown that visfatin production is enhanced during
obesity and Type 2 diabetes development [1,2], whereas
others have found that plasma visfatin is reduced in
obesity [3,4] and insulin resistance [5], and suggest that
visfatin might not be related to insulin sensitivity in
humans [6–8].
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A further conflicting point concerning the action of
visfatin is its potential role as an insulin mimetic which
was initially shown by Fukuhara et al. [1]. In fact, these
authors observed that visfatin significantly increased
glucose uptake and triacylglycerol (triglyceride) storage
in 3T3-L1 adipocytes and L6 myocytes, as well as de-
creased glucose production from hepatocytes. Moreover,
in vivo administration of visfatin to KKAy rodents
(obese and insulin-resistant) decreased circulating levels
of glucose and insulin and, thus, improved insulin sen-
sitivity, which was also observed in streptozotocin-
treated mice [1]. However, other investigators have not
observed any insulin-mimetic effects of visfatin in adi-
pogenesis, glucose uptake, insulin signalling in adipocytes
or glucose-lowering effects [9], and the original article
[1] has been retracted [10].
Little is known about the regulation of visfatin
production by adipocytes. It has been shown that glucose
stimulates visfatin release in adipocytes. This stimulatory
effect of glucose on visfatin secretion involves the PI3K
(phosphoinositide 3-kinase) and PKB (protein kinase B;
also known as Akt) pathways [11]. Moreover, visfatin
gene expression is up-regulated by glucocorticoids
and down-regulated by lipolytic agents (forskolin,
isoprenaline and cholera toxin) in 3T3-L1 adipocytes
[12,13]. However, the role played by TNF-α (tumour
necrosis factor-α) and IL-6 (interleukin-6), as well as
other pro-inflammatory cytokines in visfatin production,
is still controversial. Indeed, although some studies have
observed that TNF-α and IL-6 inhibit visfatin synthesis
in 3T3-L1 adipocytes [12,14] and in vivo [15], an assay
performed in human adipocytes has shown that treatment
with TNF-α induces an up-regulation in visfatin
production [16]. In order to better elucidate the actions
of TNF-α on this adipokine, in the present study we
analyse its short-term (24 h) and long-term (96 h) effects
on both visfatin secretion and gene expression in a model
of primary cultured rat adipocytes anchored to a collagen
matrix, which simulates basementmembrane attachment,
producing a more physiological environment [17].
A regulatory role for dietary fats, such as palmitate,
a saturated NEFA (non-esterified fatty acid; ‘free fatty
acid’) and oleate (a mono-unsaturated NEFA) on visfatin
gene expression has also been described in 3T3-L1
murine adipocytes [18].
EPA (eicosapentaenoic acid) is a dietary PUFA (poly-
unsaturated fatty acid) from the omega-3 family (n−3
PUFA). EPA has been reported to exert beneficial effects
on health, including improvements of inflammatory
conditions, obesity, insulin resistance and Type 2 diabetes
[19–22]. Some of these actions have been related to the
anti-inflammatory properties of n−3 PUFAs [19,23] and
to their ability tomodulate adipokine production, such as
adiponectin and leptin, both in vivo [19,20] and in vitro
[17,24]. In this context, a recent study by our group has
suggested that the insulin-sensitizing effects of in vivo
EPA treatment in cafeteria-fed animals could also be
related to a stimulatory action on visfatin gene expression
in visceral fat [21]; however, the direct effects of EPA on
visfatin production have not yet been studied.
Several studies have reported the regulatory role
of AMPK (AMP-activated protein kinase) activation
on adipokine production, such as adiponectin [25].
In addition, the antidiabetic efficacy of some insulin
sensitizers, such as metformin and glitazones, involves
the activation of AMPK [26]. Some studies have
suggested that AMPK activation could be involved in
EPA-induced improvements in insulin sensitivity [27].
However, controversial results have also been reported
suggesting that dietary fish oils do not activate AMPK
in mouse tissues [28]. To our knowledge, there are no
studies addressing the ability of EPA tomodulate AMPK
activation in adipocytes.
In the present study, we examined the direct effects of
EPA on visfatin gene expression and protein secretion in
both primary rat and 3T3-L1 adipocytes. Additionally,
we also investigated whether EPA activates AMPK in
3T3-L1 adipocytes and the potential involvement of this
kinase on the action of EPA on visfatin.
MATERIAL AND METHODS
Animals
Male Wistar rats were obtained from the Applied
Pharmacobiology Center (CIFA-Pamplona, Spain). The
animals were housed in cages in temperature-controlled
rooms (22+− 2 ◦C) with a light/dark cycle (12 h/12 h). All
experimental procedures were performed according to
National and Institutional Guidelines for Animal Care
and Use, with the approval of the Ethical Committee for
Animal Care and Use at the University of Navarra.
Adipocyte isolation and primary culture
Adipocytes were isolated from epididymal fat depots
of Wistar rats, as previously described [24]. Briefly, AT
fragments were digested with type I collagenase at 37 ◦C
with gentle shaking for 30 min. The resulting cell suspen-
sion was diluted in Hepes buffer (5 mmol/l d-glucose,
2% BSA, 135 mmol/l NaCl, 2.2 mmol/l CaCl2 · 3H2O,
1.25 mmol/l MgSO4 · 7H2O, 0.45 mmol/l KH2PO4,
2.17 mmol/l Na2HPO4 and 10 mmol/l Hepes, pH 7.4)
and then filtered through a 400 μmnylonmesh. The isol-
ated adipocyteswerewashed three times and resuspended
in low-glucose (5 mmol/l) DMEM (Dulbecco’s modified
Eagle’smedium) supplementedwith 1% (v/v) FBS (foetal
bovine serum) and incubated for 30–40 min at 37 ◦C.
The isolated adipocytes were plated on 500 μl of a col-
lagen matrix (Purecol; Inamed Biomaterials) in six-well
culture plates and, after 50 min incubation, culture
medium containing the different treatments was added
and cells were cultured for 24 or 96 h.
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Cell culture and differentiation
of 3T3-L1 cells
Mouse 3T3-L1 cells were purchased from American
Type Culture Collection and differentiated as described
previously [29]. Briefly, at 2 days post-confluence
pre-adipocytes were cultured for 48 h in DMEM con-
taining 25 mmol/l glucose, 10% (v/v) FBS, antibiotics
and supplemented with dexamethasone (1 μmol/l), iso-
butylmethylxanthine (0.5 mmol/l) and insulin (10 μg/
ml). Then, cells were cultured with 10% (v/v) FBS and
10 μg/ml insulin in DMEM for 48 h. Cells were then
cultured without insulin until day 6–7 post-confluence
when cells were completely differentiated to adipocytes.
Prior to the addition of the appropriate treatments, cells
were serum-starved overnight and then treated.
Treatments
EPA (Cayman Chemical) was dissolved in ethanol,
TNF-α (Phoenix Peptide) was dissolved in water, and
AICAR (5-amino-4-imidazolecarboxamide-1-β-d-ribo-
furanoside; Sigma), LY294002 (Sigma) and Compound C
(Calbiochem) were dissolved in DMSO. All compounds
were prepared as 1000× stock solutions and were then
added to the culture medium. Control cells were treated
with the same amount of the corresponding vehicle
(ethanol and/or DMSO). EPA (100 and 200 μmol/l)
and/or TNF-α (1 ng/ml) and/or the AMPK stimulator
AICAR (2 mmol/l) were added to the medium at the
same time; however, when the selective PI3K inhibitor
LY294002 (50 μmol/l) and AMPK inhibitor Compound
C (20 μmol/l) were used, adipocytes were pre-incubated
for 30 min with the inhibitors prior to the addition of
EPA (200 μmol/l).
Assays
The total amount of visfatin secreted into culturemedium
was determined through the use of an ELISA kit for
rat/mouse visfatin (Alpco Diagnostics).
Analyses of mRNA
Total RNA was extracted using TRIzol® according to
the manufacturer’s protocol (Invitrogen). Following
this, the RNAwas incubated with an RNAse-free DNase
kit (Ambion). RNA (1 μg) was reverse-transcribed to
cDNA usingMMLV (Moloney-murine-leukaemia virus)
reverse transcriptase (Invitrogen). Visfatin mRNA and
18S levels were determined by quantitative real-time
PCR using the ABI PRISM 7000HT Sequence Detection
System (Applied Biosystems). Quantitative real-time
PCR analysis was performed as previously described
[24]. Fold changes of gene expression were calculated
using the 2−Ct method.
Western blot analysis
3T3-L1 adipocytes were cultured and induced to differ-
entiate as previously described [29]. AMPK activation
was determined both in mature adipocytes (7 days
post-differentiation) and in pre-confluent (20–30%) pre-
adipocytes. Cells were serum-starved overnight (18 h)
and then incubated with the appropriate treatment.
Cells (0.5× 106) were washed in PBS, lysed in 200 μl
of double-strength SDS sample buffer containing DTT
(dithiothreitol) [60% glycerol, 150 mmol/l Tris/HCl
(pH 6.8), 2 mmol/lDTT, 2%(w/v) SDSand0.005%Bro-
mophenol Blue] and heat-denatured before resolution on
SDS/PAGE (7.5% gels). Protein immunoblotting was
performed as previously described [30]. Briefly, proteins
were transferred on to nitrocellulose membranes (Bio-
Rad Laboratories) and then stained with Ponceau Red
solution to verify equal loading of proteins. Membranes
were then blocked for 2 h at room temperature (22 ◦C) in
TBST [50 mmol/l Tris/HCl (pH 7.6), 200 mmol/l NaCl
and 0.1% Tween 20] with 2% (w/v) BSA (fraction V;
Sigma) containing 10% (w/v) non-fat dried skimmed
milk, washed twice and then incubated overnight with an
anti-(phospho-AMPKα) (Thr172) antibody (Cell Signal-
ing Technology) diluted 1:1000. After further washings,
membranes were incubated with horseradish peroxidase-
conjugated IgG fraction of goat anti-rabbit IgG (Cell
Signaling Technology) diluted 1:5000 in TBST for 1 h.
Phospho-AMPKα (Thr172) was visualized on Amersham
Hyperfilm (GE Healthcare) using the CL+Chemi-
luminescence kit (GE Healthcare). For reprobing of the
Western blots, antibodies were stripped frommembranes
using stripping buffer [62.5 mmol/l Tris/HCl (pH 6.8),
2% (w/v) SDS and 100 mmol/l 2-mercaptoethanol] for
30 min at 50 ◦C, washing the membranes with TBST and,
after making sure that the original signal was removed,
we reprobed with AMPKα (Cell Signaling Technology)
diluted 1:1000 and incubated overnight. Then, the bands
were visualized as described above.
Data analysis
Results are means +− S.E.M. The statistical analysis was
performed by repeated measures one-way ANOVA, fol-
lowed by a Dunnet’s post-hoc test, or by a two-way AN-
OVA. Differences were considered as statistically signi-
ficant at P< 0.05. The statistical analyses were performed
using GraphPad Prism software (GraphPad Software).
RESULTS
Effects of EPA on visfatin secretion in
primary cultured rat adipocytes
Incubation of primary rat adipocytes with EPA at
200 μmol/l induced an increase in basal visfatin secretion
as compared with control cells both at 24 h (169.7+−
18.0% of control, P< 0.001) and 96 h (122.5+− 10.8%
of control, P< 0.05) of treatment (Figure 1A). This
stimulatory effect of EPA on visfatin seems to be
dose-dependent, since no significant changes in visfatin
release were observed when adipocytes were incubated
with lower doses of EPA (results not shown).
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Figure 1 Effects of EPA and TNF-α on visfatin secretion and
mRNA levels
(A) Effects of EPA (200 μmol/l) and TNF-α (1 ng/ml) on visfatin secretion
in isolated primary cultured rat adipocytes over 24 and 96 h of treatment.
∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 as compared with control. (B)
Visfatin mRNA gene expression levels after 24 h of EPA treatment with and without
TNF-α. Gene expression data were analysed by two-way ANOVA (∗P < 0.05).
Results are representative of at least five independent experiments. T, TNF-α;
E, EPA; TxE, interaction between TNF-α and EPA treatments.
Taking into account that some studies have described
that TNF-α alters visfatin production in adipocytes,
we tested the effects of the pro-inflammatory cytokine
in our model of primary cultured rat adipocytes and
their potential ability to reverse the stimulatory actions
of EPA on visfatin. However, in the model of cultured
adipocytes used in the present study, the presence of
the pro-inflammatory cytokine TNF-α (1 ng/ml) did
not modify visfatin secretion after short-term (24 h) or
long-term (96 h) treatment. Interestingly, the stimulatory
effect of 200 μmol/l EPA on visfatin secretion was also
observed in the presence of TNF-α in the medium.
The expression pattern of the visfatin gene after 24 h
of treatment was similar to that observed for visfatin
secretion. Thus incubation of adipocytes with EPA alone
or in combination with TNF-α significantly increased
visfatin mRNA gene expression levels (Figure 1B).
Effects of AICAR, Compound C and
LY294002 on EPA-stimulated visfatin
production in primary cultured rat
adipocytes and murine 3T3-L1 adipocytes
Using the samemodel of primary cultured rat adipocytes,
we observed that treatment with the AMPK inhibitor
Compound C (20 μmol/l) abolished the stimulatory
action of EPA on visfatin release. We also determined
the effects of EPA (200 μmol/l) in combination with the
AMPK stimulator AICAR (2 mmol/l). Interestingly, co-
treatment of EPA+AICAR further stimulated visfatin
production (163.8+− 20.1% of control for EPA, P< 0.01
and 185.1+− 23.3% of control for EPA+AICAR-treated
cells, P< 0.01), suggesting a certain additive effect of
both agents. However, the PI3K inhibitor LY294002
(50 μmol/l) did not significantly modify the stimulatory
effect induced by EPA on visfatin secretion (Figure 2A).
In order to verify the role of AMPK in the stimulatory
action of EPA on visfatin, we also tested the ability of
Compound C to reverse EPA actions on visfatin in 3T3-
L1 adipocytes. In agreement with the results observed in
primary adipocytes, incubation of mature 3T3-L1 adipo-
cytes with EPA (200 μmol/l) induced a strong increase in
visfatin secretion after treatment for 24 h (130.2+− 13.4%
of control, P< 0.05). Interestingly, this effect was
significantly prevented (P< 0.01) by the addition of the
AMPK inhibitor Compound C (Figure 2B), but not with
the PI3K inhibitor LY294002 (results not shown), as
previously observed in primary cultured rat adipocytes.
The pattern of the effects of EPA on visfatin gene
expression was similar to the results obtained for visfatin
secretion in 3T3-L1 adipocytes. Thus visfatin mRNA
levels were significantly (P< 0.05) enhanced after 24 h of
treatment with 200 μmol/l EPA, whereas the presence
of Compound C prevented the stimulatory effect of EPA
on visfatin gene expression (Figure 2C). These findings
suggest a potential involvement of AMPK on EPA-
stimulated visfatin production in murine adipocytes.
Effects of EPA on AMPK activation in
3T3-L1 adipocytes
Inorder to assesswhetherEPAdirectly stimulatesAMPK
activation, 3T3-L1 adipocytes and pre-adipocytes were
treated with EPA (100 μmol/l and 200 μmol/l).
Incubation of both 3T3-L1 mature adipocytes
(Figure 3A) and pre-adipocytes (Figure 3B) with EPA
resulted in a positive activation of AMPK in a dose-
dependent manner. In contrast, the pro-inflammatory
cytokine TNF-α (1 ng/ml) did not phosphorylate
AMPK (Thr172) in 3T3-L1 adipocytes. Interestingly, the
presence of EPA (100 and 200 μmol/l) in TNF-α-treated
adipocytes also stimulated AMPK phosphorylation to
similar levels to that which was observed in adipocytes
treated with EPA alone. As expected, AICAR (2 mmol/l)
induced a strong increase in AMPK activation, whereas
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Figure 2 Role of AMPK and PI3K/PKB signalling pathways on EPA-stimulated visfatin secretion and mRNA levels
(A) Effects of EPA (200 μmol/l) on visfatin secretion alone or in the presence of AICAR (2 mmol/l), Compound C (20 μmol/l) or LY294002 (50 μmol/l) after 24 h
of treatment in primary cultured rat adipocytes. Effects of EPA (200 μmol/l) on visfatin secretion (B) and mRNA gene expression (C) in the absence or presence of
Compound C (20 μmol/l) in 3T3-L1 adipocytes. ∗P < 0.05 and ∗∗P < 0.01 as compared with control cells; bP < 0.01 as compared with EPA-treated cells. Results
are representative of four to six independent experiments.
Figure 3 Effects of EPA on AMPK activation with or without
TNF-α, AICAR and Compound C
Analysis of AMPK activation in 3T3-L1 adipocytes (A) and pre-adipocytes (B)
30 min after treatment with EPA (100 and 200 μmol/l) in the presence and
absence of TNF-α (1 ng/ml), AICAR (2 mmol/l) and Compound C (20 μmol/l).
Whole-cell lysates were subjected to gel electrophoresis and immunoblotted using
specific antibodies for phospho-AMPKα (Thr172) and AMPKα as described in
the Material and methods section. The blots shown are representative of three
independent experiments showing the effects of different treatments on AMPK
phosphorylation. p-AMPK, phospho-AMPK.
the co-treatment with Compound C (20 μmol/l) was
able to partially block the AMPK phosphorylation
induced by both EPA and AICAR.
All of these results clearly demonstrate the ability
of EPA to activate AMPK phosphorylation (Thr172) in
3T3-L1 cells (both adipocytes and pre-adipocytes).
DISCUSSION
Several studies have reported the ability of n−3 PUFAs to
improve insulin sensitivity by controlling adipokine pro-
duction [22]. In fact, EPA regulates leptin and adiponectin
production in vitro [17,24] and in vivo [19,27,31].
A recent study by our group also demonstrated the
ability of EPA ethyl ester administration to prevent
the decrease in visfatin gene expression observed in high-
fat-diet-induced obese rats [21]. An inverse relationship
with HOMA (homoeostasis model assessment), an index
of insulin resistance, was also found, suggesting that
the insulin-sensitizing effects of EPA could be related
to its stimulatory action on visfatin gene expression in
visceral fat [21]. In the present study, the finding that a
direct stimulatory effect of EPA on both visfatin gene
expression and protein secretion in primary adipocytes
is relevant. Thus it suggests that the up-regulation of
visfatin gene suggested in visceral AT observed in our
previous study after in vivo EPA administration was not
only due to the reducing effects of EPA treatment on the
size of this fat depot, but also by a direct transcriptional
up-regulation of the visfatin gene by this n−3 PUFA.
Other studies have reported the ability of dietary fatty
acids to modulate visfatin gene expression. In contrast
with the n−3 PUFA EPA, the saturated NEFA palmitate
and mono-unstaturated NEFA oleate down-regulated
visfatin mRNA gene expression in 3T3-L1 adipocytes
and pre-adipocytes [18]. Moreover, this down-regulation
of visfatin was suggested as a potential mechanism to
directly induce insulin resistance by oleate and palmitate
in vitro [18]. In this context, it has also been shown that
a synthetic mixture including stearate, oleate, linoleate,
linolenate and arachidonate normalized the increase in
visfatin release induced by treatment with the insulin-
sensitizing PPAR-γ (peroxisome-proliferator-activated
receptor-γ ) agonist rosiglitazone in human isolated
adipocytes [32]. These findings suggest a differential
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regulation of visfatin depending of the type of dietary fat
and support our hypothesis that visfatin up-regulation
by EPA could be another mechanism by which n−3
PUFAs may improve insulin sensitivity.
We have testedwhether incubationwith 1 ng/ml TNF-
α, a dose known to induce lipolysis and inflammatory
markers in our model of cultured adipocytes (results not
shown), was able to reverse the EPA-stimulated visfatin
secretion. Our results have revealed that TNF-α did
not induce any significant change in visfatin secretion,
both in the presence or absence of EPA after 24 and
96 h of treatment. This fact suggests that, in our culture
conditions, the stimulatory action of EPA on visfatin
seems not to be related to the ability of n−3 PUFAs
to block the inflammatory pathway [19]. The available
data in the literature concerning the regulation of visfatin
bypro-inflammatory cytokines are controversial. Indeed,
some studies have observed that TNF-α and IL-6 induced
a time- and dose-dependent down-regulation of visfatin
gene expression levels in 3T3-L1 adipocytes [12,14].
However, an assay performed in human adipocytes has
shown that visfatin mRNA levels were highly increased
after 24–72 h of incubation with TNF-α [16]. The dis-
parity observed may be related to differences in the type
(primary comparedwith cell lines) and source (rat, mouse
or human) of cultured adipocytes, the concentration of
TNF-α used and the duration of the treatment.
AMPK is a protein kinase that regulates important
metabolic processes, whose activation induces multiple
effects on liver, AT and muscle metabolism [33]. AMPK
activation has been associated with the regulation of
adipokine production, such as adiponectin [25]. Recently,
long-chain fatty acyl analogues, which are AMPK activ-
ators, have been proposed as potential agents for treating
Type 2 diabetes [34]. Thus some studies have suggested
that AMPK activation could be involved in EPA-induced
improvements in insulin sensitivity [27], although there
was no data showing evidence of a direct activation of
AMPK by EPA in adipocytes. Our present study clearly
demonstrated that treatment of adipocytes with EPA
strongly stimulatedAMPKactivation.These results are in
accordance with previously published studies which re-
ported that PUFAs induced activation of this signal trans-
duction protein in liver [35].Moreover, a recent study also
demonstrated an increase in intestinal glucose absorption
potentially via acute activationofAMPKaftern−3PUFA
feeding during gestation in pigs [36]. However, other
investigators did not find any changes in AMPK phos-
phorylation in mouse tissues (liver, skeletal muscle and
heart) after feeding a diet supplemented with fish oil [28].
An interesting finding of the present study was that
the stimulatory effect of EPA on visfatin secretion in
adipocytes involved the AMPK-activation pathway, but
not PI3K. In support of the present study, recent work
performed in myocytes has also demonstrated that cells
exposed to AICAR or glucose restriction, which also
increase AMPK activity, had increased Nampt/visfatin
mRNA expression and protein levels, indicating that
AMPK regulates Nampt expression induced by glucose
restriction in these insulin-target cells [37].
EPA has been shown to stimulate the PI3K pathway
in hepatoma cells [38] and adipocytes (results not
shown). Moreover, glucose-stimulated visfatin secretion
involves the PI3K/PKB pathway [11]. However, the
fact that PI3K inhibitor treatment did not modify
EPA-stimulated visfatin release either in primary rat
or 3T3-L1 adipocytes suggests that the PI3K signalling
pathway is not likely to be involved in the stimulatory
effect of EPA on visfatin secretion.
In summary, our results show for the first time
that EPA increases visfatin expression and secretion
in primary adipocytes, and that AMPK activation is
intimately involved in the EPA-stimulatory action in
visfatin production. These mechanisms could account
for the insulin-sensitizing actions of EPA.
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